Description of Business and Basis of Presentation - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended
	Feb. 17, 2023	Dec. 31, 2022	Dec. 31, 2021
Inventory [Line Items]
Inventory		$ 18,515	$ 17,980
Accumulated deficit		(222,758)	(143,422)
Restructuring charges		1,448
Subsequent Event
Inventory [Line Items]
Aggregate gross proceeds from conversion of preferred stock and warrants to common stock	$ 30,000
Customers For Which Returns Are Expected To Be Received
Inventory [Line Items]
Accrued sales returns resulting from FDA Warning Letter		$ 4,958	$ 20,145